Press Releases

pSivida Corp. Announces Fourth Quarter and Fiscal Year 2016 Financial Results Release Date and Conference Call Information Sep 01, 2016 WATERTOWN, Mass. , Sept. 01, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products primarily for treating eye diseases, today announced its financial results for the fourth quarter and fiscal year 2016 will be Read more
pSivida Announces 13 New Patents Issued or Allowed Aug 29, 2016 U.S. and foreign patents for bioerodible Medidur™, new smaller needle Medidur injector and Tethadur™ Read more
Topline Results from First Phase 3 Trial of pSivida's Medidur™ Presented at ASRS Annual Meeting Aug 15, 2016 WATERTOWN, Mass. , Aug. 15, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products primarily for eye diseases, announced that Dr. Glenn J. Jaffe , Robert Machemer Professor of Ophthalmology at Duke University School of Read more
Primary Endpoint Met in pSivida's Utilization Study of New Medidur™ Inserter with Smaller Diameter Needle Aug 09, 2016 Results to Form Part of Planned Applications for Marketing Approvals in EU and US Read more
pSivida Names Dario Paggiarino, M.D. as Chief Medical Officer Aug 03, 2016 Industry Veteran Brings Over 25 Years of Pharmaceutical and Drug Development Experience Read more
pSivida Corp and Hospital for Special Surgery Innovation Center Announce Opening of IND for Sustained-Release Implant for Severe Knee Osteoarthritis Aug 01, 2016 WATERTOWN, Mass. and NEW YORK , Aug. 01, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for eye diseases, and Hospital for Special Surgery (HSS), America's leading specialty hospital devoted to orthopedics and Read more
pSivida's Medidur™ Maintains Same High Statistical Significance in Primary Endpoint through 12 Months in First Phase 3 Trial (p Less Than 0.00000001) Jul 27, 2016 Incremental Risk of Elevated IOP Relative to Control Decreases Through Last Follow-up Visit Read more
Data Shows pSivida's Tethadur™ Provides Prolonged, Sustained Release of Avastin® With High Drug Efficacy Jul 20, 2016 Data Presented at 2016 Annual Meeting & Exposition of the Controlled Release Society Read more
pSivida Corp. Announces Plan to Consolidate all Research and Development in Current U.S. Facility Jul 15, 2016 Plan to Facilitate Product Development and Reduce Operating Expenses Read more
Investigator-Sponsored Phase 2 Study Results Show pSivida's Medidur® Fully Controlled Uveitis for Two Years with No Recurrence of Disease While Visual Acuity Continued to Improve Jul 14, 2016 Study Results Showing No Recurrence of Disease and Statistically Significant Improvement in Visual Acuity to be Published in Ophthalmology Read more
pSivida Announces Poster and Oral Presentation on Controlled Release of Avastin® from Tethadur™ Biodegradable Matrix at the 2016 Controlled Release Society Annual Meeting Jul 08, 2016 WATERTOWN, Mass. , July 08, 2016 (GLOBE NEWSWIRE) -- pSivida Corp (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products primarily for eye diseases, announced that pSivida's Dr. Catherine Kelly will present a poster and oral presentation on "The Controlled Read more
pSivida Announces Successful Completion of Two Preclinical Studies of Durasert™ Sustained-Release Insert Delivering Repurposed Cancer Drug to Treat Wet AMD Jul 05, 2016 Promising Results for Potential Sustained Treatment of Wet AMD Using a TKI Read more
pSivida Corp. Provides Company Update and Reports Third Quarter FY 2016 Results May 05, 2016 WATERTOWN, Mass. , May 05, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today provided a Company update and announced financial results for its third fiscal quarter ended March 31, Read more
pSivida CEO to Present at 2016 International Symposium of Ocular Pharmacology and Therapeutics May 04, 2016 WATERTOWN, Mass. , May 04, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that Dr. Paul Ashton , president and CEO, will present "Changing the Treatment Paradigm Read more
pSivida's Medidur for Posterior Uveitis Granted Orphan Drug Designation in Europe May 02, 2016 WATERTOWN, Mass. , May 02, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that the European Commission granted orphan medicinal product designation to Medidur™ for Read more
pSivida Corp. Announces Third Quarter Fiscal Year 2016 Financial Results Release Date and Conference Call Information Apr 27, 2016 WATERTOWN, Mass. , April 27, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that its financial results for the third quarter of fiscal year 2016 will be released after Read more
pSivida to Present at the Sidoti Spring 2016 Emerging Growth Convention Mar 24, 2016 WATERTOWN, Mass. , March 24, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that the company will be presenting at the Sidoti Spring 2016 Emerging Growth Convention at Read more
Additional Favorable Six-Month Safety Results for pSivida's Medidur™ for Posterior Uveitis Mar 15, 2016 Small Average Increase in IOP Relative to Control Comparable Percentage Treated with Eye Drops for Elevated IOP WATERTOWN, Mass. , March 15, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye Read more
pSivida Corp. Provides Company Update and Reports Second Quarter FY 2016 Results Feb 08, 2016 WATERTOWN, Mass. , Feb. 08, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV), (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today provided a Company update and announced financial results for its second fiscal quarter ended Read more
pSivida Corp Announces Second Quarter Fiscal Year 2016 Financial Results Release Date and Conference Call Information Feb 01, 2016 WATERTOWN, Mass. , Feb. 01, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that its financial results for the second quarter of fiscal year 2016 will be released after Read more

pSivida Corp. Announces Fourth Quarter and Fiscal Year 2016 Financial Results Release Date and Conference Call Information

Sep 01, 2016

pSivida Announces 13 New Patents Issued or Allowed

Aug 29, 2016

Topline Results from First Phase 3 Trial of pSivida's Medidur™ Presented at ASRS Annual Meeting

Aug 15, 2016

Primary Endpoint Met in pSivida's Utilization Study of New Medidur™ Inserter with Smaller Diameter Needle

Aug 09, 2016

pSivida Names Dario Paggiarino, M.D. as Chief Medical Officer

Aug 03, 2016

pSivida Corp and Hospital for Special Surgery Innovation Center Announce Opening of IND for Sustained-Release Implant for Severe Knee Osteoarthritis

Aug 01, 2016